A Biomimetic, Stem Cell‐Derived In Vitro Ocular Outflow Model. Issue 9 (30th July 2020)

• Record Type: Journal Article
• Authors: Tian, Yangzi Isabel; Zhang, Xulang; Torrejon, Karen; Danias, John; Du, Yiqin; Xie, Yubing
• Is Part Of: Advanced biosystems. Volume 4:Issue 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-30
• Subjects: 3D culture -- glaucoma -- microfabrication -- outflow -- stem cell -- trabecular meshwork; Biological systems -- Periodicals; Biotechnology -- Periodicals; Bioengineering -- Periodicals; Biomedical engineering -- Periodicals; Biological Science Disciplines; Periodicals; Periodicals; 660.6
• DOI: 10.1002/adbi.202000004
• Languages: English
• ISSNs: 2366-7478

Abstract

Abstract: Age‐related human trabecular meshwork (HTM) cell loss is suggested to affect its ability to regulate aqueous humor outflow in the eye. In addition, disease‐related HTM cell loss is suggested to lead to elevated intraocular pressure in glaucoma. Induced pluripotent stem cell (iPSC)‐derived trabecular meshwork (TM) cells are promising autologous cell sources that can be used to restore the declining TM cell population and function. Previously, an in vitro HTM model is bioengineered for understanding HTM cell biology and screening of pharmacological or biological agents that affect trabecular outflow facility. In this study, it is demonstrated that human iPSC‐derived TM cells cultured on SU‐8 scaffolds exhibit HTM‐like cell morphology, extracellular matrix deposition, and drug responsiveness to dexamethasone treatment. These findings suggest that iPSC‐derived TM cells behave like primary HTM cells and can thus serve as reproducible and scalable cell sources when using this in vitro system for glaucoma drug screening and further understanding of outflow pathway physiology, leading to personalized medicine. Abstract : To address the unmet need of reproducible and scalable cell sources that can be used for in vitro outflow pathway model, human induced pluripotent stem cell‐derived trabecular meshwork (TM) cells are cultured on biocompatible SU‐8 scaffolds, exhibiting TM‐like cell morphology, extracellular matrix deposition, and drug responsiveness to steroid treatment.